Contact-02: A Phase III Trial Shaping the Future of Metastatic Prostate Cancer Care - Neeraj Agarwal

November 22, 2022

Alicia Morgans converses with Neeraj Agarwal about the ongoing phase III Contact-02 Trial, designed for patients with metastatic castrate-resistant prostate cancer (CRPC) who show disease progression on a novel hormonal therapy or androgen receptor inhibitor. Patients eligible for this trial should have measurable disease, which may include extra pelvic lymphadenopathy or visceral metastasis. Dr. Agarwal further explains the Contact-02 Trial's design, which randomizes patients to an alternative novel hormonal therapy or a unique combination of Cabozantinib and Atezolizumab. He also mentions that Cabozantinib, a multityrosine kinase inhibitor, may alter the tumor microenvironment, possibly boosting the effectiveness of the accompanying immunotherapy. The trial's primary endpoints are overall survival and radiographic progression-free survival. For those interested in the trial, Dr. Agarwal suggests visiting and searching "Contact-02" to find additional information and how to get involved.


Neeraj Agarwal, MD, Clinical Research Innovation, University of Utah Health - Huntsman Cancer Institute, Salt Lake City, UT

Alicia Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts

Read the Full Video Transcript

Alicia Morgans: Hi. I'm so excited to be here with Dr. Neeraj Agarwal. We're talking about the Contact-02 Trial for patients with metastatic CRPC. Neeraj, thank you so much for being here. Can you set up the trial design for us please?

Neeraj Agarwal: Contact-02 is a phase III trial. It's a randomized trial in patients who have had disease progression on a novel hormonal therapy or androgen receptor inhibitor, such as Enzalutamide, Apalutamide, or Abiraterone. And now, they have progressive metastatic castrate-resistant prostate cancer with measurable disease. So, this is one of the main eligibility criteria. And they either can have extra pelvic lymphadenopathy, or they can have visceral metastasis, which has to be measurable. So, in this context, Contact-02 Trial is randomizing patients to an alternative novel hormonal therapy versus the novel combination of Cabozantinib with Atezolizumab. For the viewers, Cabozantinib is a multityrosine kinase inhibitor, including MET, which is known to be upregulated when patients or tumors are treated with androgen receptor inhibitors. The primary endpoints of this trial are overall survival and radiographic progression-free survival. And this trial is currently accruing patients in multiple countries in the world.

Alicia Morgans:
And it's so exciting. I think, importantly, just to emphasize, and then I'll ask you how people can get involved, where they can find information about the trial. But importantly, as you said, this is only for patients with measurable disease. And really this novel combination is so exciting, thought to potentially be active in settings where the Cabozantinib might be changing the tumor microenvironment, and then allowing this immunotherapy to be so effective. But we will see, and we need patients to continue to enroll in this trial, so that we can have an answer for our community. So, if people are interested in getting engaged, how can they look into this trial or have their physicians look into it?

Neeraj Agarwal:
So, is the open website where if you type "Contact-02," you will find the information on all these sites which are open not only in the United States, but also across the world. And the phone numbers are usually available there, or the email information is there. So, depending upon where you live, you can look up, call the phone number, and I'm sure there will be an immediate response.

Alicia Morgans: Wonderful. Well, thank you so much for sharing this information. I really look forward to seeing where this combination takes us, and of course, your continued leadership in this study, but also across the field. Thank you for your time and expertise.

Neeraj Agarwal: Thank you very much for having me.